

---

Macrolides, Ketolides,  
Lincosamides, Streptogramins,  
Linezolid, Chloramphenicol

---

**Dr. Erzsébet Kató**

**[kato.erszebet@med.semmelweis-univ.hu](mailto:kato.erszebet@med.semmelweis-univ.hu)**

**[www.semmelweispharma.com](http://www.semmelweispharma.com)**

---

# Macrolides

---



---

# History

- Erythromycin - 1952- penicillin allergy
  - 1970- **ATYPICAL** pathogens (Legionella, Chlamydia, Mycoplasma)
-

---

## Natural

- Erythromycin
- Spiramycin
- Josamycin

## Semisynthetic

- Roxithromycin
  - Clarithromycin
  - Azithromycin
-

---

# Mechanism of action

- Inhibition of protein synthesis via binding to the 50S ribosomal RNA
  - Bacteriostatic (sometimes bactericid)
  - Time dependent effect
-

---

# Resistance

- Mechanisms:
    - Modification of the ribosomal binding site (MLS<sub>B</sub> – Macrolides-Lincosamides-Streptogramin B)
    - Inactivation (esterases)
    - Decreased permeability – efflux
-

---

# Antibacterial activity

- **G +** : Streptococci sp., Staphylococci sp., Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus Anthracis
  - **G -** : Neisseria sp., Bordetella pertussis, Hemophilus sp., (Azithromycin) Campylobacters, H. pylori (Clarithromycin)
  - **Atypical organisms**: Chlamydia sp., Legionella sp., Mycoplasma sp., Ureaplasma urealyticum
  - Spirochetes: Treponema pallidum, Borrelia burgdorferi
  - Toxoplasma gondii (Spiramycin)
-

# Resistant bacteria

- Gram-negative GI tract bacteria → natural resistance
- Pneumococci strains – many of them might be resistant
- MRSA
- Enterococci
- Pseudomonas
- Acinetobacter
- Bacteroides fragilis





---

# Pharmacokinetics

- Well absorbed given orally (exception – Erythromycin)
  - Good distribution
  - Excretion mainly in the bile (erythromycin) or by the urine (clarythromycin)
  - Taken up by **ACTIVE TRANSPORT** into macrophages (IC effectivity!!!)
-

---

# Adverse effects

- **NON TOXIC**, safe in pregnancy (exception Clarithromycin- might be teratogenic)
  - Gastrointestinal (nausea, vomit, diarrhea) – mainly Erythromycin (motilin), the others cause less.
  - Erythromycin and Clarithromycin inhibit the cytochrome P450 enzymes, Azithromycin does not.
-

---

# Indications

- Upper respiratory tract infections in case of penicillin allergy
  - Atypical pneumonias
  - Chlamydia urethritis (Azithromycin)
  - Toxoplasmosis in pregnancy (Spiramycin)
  - Campylobacter jejuni gastroenteritis
  - H. pylori eradication (Clarithromycin)
  - Diphtheria, whooping cough, early Lyme syndrome (Azithromycin)
-

---

# Ketolides - Telithromycin

- Semisynthetic macrolide antibiotic
  - Differences:
    - Binds with a higher affinity to the 50S subunit
    - Bactericid, concentration dependent effect
    - Antibacterial activity is similar to the activity of macrolides but can be effective in case of macrolide resistant strains as well
    - hepatotoxicity (rare)
-



---

# Lincosamides - Clindamycin

---



---

# Mechanism of action

- Inhibition of protein synthesis via binding to the 50S ribosomal RNA
  - Bacteriostatic
-

---

# Resistance

- Mechanisms:
    - Modification of the ribosomal binding site (MLS<sub>B</sub> – Macrolides-Lincosamides-Streptogramin B)
    - Efflux
-



# Antibacterial activity

- **G +** : Streptococci sp., Staphylococci sp.
- **Anaerobs**: Gram-positive > Gram-negative
  - Gram-positive: Clostridium sp., (exception Clostridium difficile), Actinomyces sp.
  - Gram-negative: Bacteroides sp., Fusobacterium sp., Prevotella sp.,
- Chlamydia trachomatis
- Some protozoons: Plasmodium falciparum, Toxoplasma gondii, Pneumocystis jiroveci (carinii)

# Resistant bacterias

- Gram-negative aerob bacterias → natural resistance
- Enterococci strains
- Staphylococci – many resistant strains
- Mycoplasma pneumoniae
- Clostridium difficile



---

# Pharmacokinetics

- Well absorbed given orally
  - Good distribution, into abscesses, **BONES** as well! Does not enter CNS
  - Metabolized in the liver
  - Accumulates intracellularly
-

---

# Adverse effects

- Nausea, diarrhea
  - Pseudomembranous colitis caused by *Clostridium difficile* → treatment Metronidazol or Vancomycin
  - Skin rashes
  - Neutropenia (rare)
-

---

# Indications

- **Odontogenic infections! – ex. periodontitis, periodontal abscess**
  - Osteomyelitis
  - Aspiration pneumonia, lung abscess
  - Polymicrobial abdominal infections (in combination with antibiotics active against Gram negative aerobs)
  - Skin and soft tissue infections (diabetic foot, gangrene)
  - Toxic shock syndrome
-



---

# Streptogramins

---



---

# Compounds

- We use a fix combination of Dalfopristin (A) and Quinupristin (B)
  - They have **synergic** effect in combination
  - Inhibit protein synthesis via binding to the 50S ribosomal RNA
  - Bactericid effect
-



---

# Resistance

- Mechanisms:
    - Modification of the ribosomal binding site in case of Quinupristin (MLS<sub>B</sub> – Macrolides-Lincosamides-Streptogramin B)
    - Enzymatic inactivation of Dalfopristin
    - Efflux
-

---

# Antimicrobial activity

- Effective „**ONLY**” against **G +** cocci
    - Streptococci sp., PRSP
    - Staphylococci sp., MRSA, VRSA
    - Enterococci sp., VRE
-

---

# Resistant bacterias

- Gram-negative bacterias
- Enterococci faecalis



---

# Pharmacokinetics

- Administered intravenously
  - Do not cross blood brain barrier
  - Metabolized in the liver, eliminated mainly through the biliary tract
-

---

# Adverse effects -rare

- Phlebitis
  - Arthralgia – Myalgia syndrome
  - Inhibit CYP3A4
-

---

# Indications

Severe infections caused by multiresistant Gram-positive bacterias (staphylococci, streptococci, enterococci)

---



---

# Linezolid (Oxazolidinone)

---





---

# Mechanism of action

- Inhibit protein synthesis
- it binds on 23S ribosomal RNA of the 50S subunit (*no cross resistancy!*)
- Primarily bacteriostatic, also bactericidal against *streptococci*

## Resistance

- Modification of the ribosomal binding site
-

---

# Antimicrobial activity

- Effective against **G +** cocci:
    - Streptococci sp., PRSP
    - Staphylococci sp., MRSA, VRSA
    - Enterococci sp., VRE
  - Gram positive anaerobs and rods (Corynebacterias)
  - Mycobacterium tuberculosis
-

---

# Resistant bacteria

- Gram-negative bacteria



---

# Pharmacokinetics

- Good oral availability, intravenous administration is also possible
  - CNS effect (!)
  - Metabolized in the liver
  - no interaction with cytochrom P450 enzymes
-

---

## Adverse effects -rare

- Mainly hematologic (thrombocytopenia, neutropenia)
  - peripheral neuropathy at long administration
  - Serotonin Syndrome (co-administered with serotonergic drugs)
-

# Indications

- Severe infections caused by multiresistant Gram-positive bacterias (staphylococci, streptococci, enterococci- especially Vancomycin resistant E. faecium)
  - pneumonia
  - skin and soft tissue infections
  - multidrug resistant tuberculosis (off label)
-



---

# Chloramphenicol

---





---

# Mechanism of action

- Inhibits protein synthesis via binding to the 50S ribosomal RNA
- bacteriostatic, in case of highly susceptible strains (H. influenzae, Neisseria, Bacteroides) bactericidal

## Resistance

- inactivation by acetyl transferase
-

---

# Antimicrobial activity

- Broad spectrum (!)
  - Effective against
    - anaerobic **G** + and **G**- organisms
    - Rickettsiae
-

---

# Pharmacokinetics

- Good oral availability, intravenous administration is also possible
  - excellent tissue and body fluid distribution
  - Metabolized in the liver by glucuronide conjugation
-

---

# Adverse effects

- gastrointestinal (nausea, vomit, diarrhea), alteration of the microbial flora
  - dose related reversible suppression of red cell production
  - aplastic anemia (idiosyncratic reaction)
  - gray baby syndrome
-

---

# Indications

- ❑ severe rickettsial infection below the age of 9
  - ❑ meningitis (if there is allergy to penicillins, cephalosporins)
  - ❑ brain abscess (if metronidazole + cephalosporines are not effective)
-

